|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-5-22
|
|
pubmed:abstractText |
To prospectively compare the safety and efficacy of combination therapy with the glycoprotein IIb/IIIa antagonist abciximab plus the third-generation thrombolytic agent reteplase versus those of therapy with the standard thrombolytic agent urokinase plus abciximab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa...,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/Urokinase-Type Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/abciximab,
http://linkedlifedata.com/resource/pubmed/chemical/reteplase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0033-8419
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) RSNA, 2006.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
239
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
892-900
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16641342-Adult,
pubmed-meshheading:16641342-Aged,
pubmed-meshheading:16641342-Aged, 80 and over,
pubmed-meshheading:16641342-Amputation,
pubmed-meshheading:16641342-Antibodies, Monoclonal,
pubmed-meshheading:16641342-Arterial Occlusive Diseases,
pubmed-meshheading:16641342-Drug Combinations,
pubmed-meshheading:16641342-Female,
pubmed-meshheading:16641342-Fibrinolytic Agents,
pubmed-meshheading:16641342-Follow-Up Studies,
pubmed-meshheading:16641342-Hemorrhage,
pubmed-meshheading:16641342-Humans,
pubmed-meshheading:16641342-Immunoglobulin Fab Fragments,
pubmed-meshheading:16641342-Longitudinal Studies,
pubmed-meshheading:16641342-Male,
pubmed-meshheading:16641342-Middle Aged,
pubmed-meshheading:16641342-Peripheral Vascular Diseases,
pubmed-meshheading:16641342-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:16641342-Prospective Studies,
pubmed-meshheading:16641342-Recombinant Proteins,
pubmed-meshheading:16641342-Recurrence,
pubmed-meshheading:16641342-Safety,
pubmed-meshheading:16641342-Thrombolytic Therapy,
pubmed-meshheading:16641342-Time Factors,
pubmed-meshheading:16641342-Tissue Plasminogen Activator,
pubmed-meshheading:16641342-Treatment Outcome,
pubmed-meshheading:16641342-Urokinase-Type Plasminogen Activator
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
|
|
pubmed:affiliation |
Department of Diagnostic Radiology, University of Tübingen, Tübingen, Germany. gunnar.tepe@med.uni-tuebingen.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
